METALLOTHIONEIN EXPRESSION IN NORMAL, HYPERPLASTIC, AND NEOPLASTIC THYROID FOLLICULAR AND PARAFOLLICULAR C-CELLS USING MONOCLONAL ANTIMETALLOTHIONEIN ANTIBODY-E9

Citation
Kw. Schmid et al., METALLOTHIONEIN EXPRESSION IN NORMAL, HYPERPLASTIC, AND NEOPLASTIC THYROID FOLLICULAR AND PARAFOLLICULAR C-CELLS USING MONOCLONAL ANTIMETALLOTHIONEIN ANTIBODY-E9, Endocrine pathology, 5(2), 1994, pp. 114-122
Citations number
34
Categorie Soggetti
Pathology,"Endocrynology & Metabolism
Journal title
ISSN journal
10463976
Volume
5
Issue
2
Year of publication
1994
Pages
114 - 122
Database
ISI
SICI code
1046-3976(1994)5:2<114:MEINHA>2.0.ZU;2-V
Abstract
Metallothioneins (MTS) are a set of ubiquitous low molecular proteins with a high affinity for metal ions, such as zinc, copper, and cadmium . MT overexpression can be induced by these metal ions as well as by o ther endogenous and exogenous factors. In this study, normal, hyperpla stic, and neoplastic thyroid tissues of both follicular and C-cell ori gin were immunohistochemically investigated with a monoclonal antibody against I- and II-isoforms of MTs. MT immunoreactivity was demonstrat ed in the follicular epithelium of 19 normal thyroid glands and in all 32 cases of Graves' disease investigated; 26 of 30 follicular adenoma s and 25 of 28 follicular carcinomas showed MT immunoreactivity, where as only 7 of 20 papillary carcinomas were MT-positive (p < 0.0001). In 3 of the 7 positive samples, positivity was restricted to follicular areas of differentation. No MT could be immunolocalized in normal and hyperplastic C cells and medullary thyroid carcinomas (n = 20). In mix ed medullary-follicular carcinomas (n = 4), MT staining patterns resem bled those seen for thyroglobulin. In anaplastic carcinomas, MTs were mainly immunolocalized in nonspindle cell areas. MT expression in thyr oid tumors may reflect the different biological behavior of follicular and papillary carcinomas. Antibodies to MTs may also serve as fairly specific immunohistochemical markers of follicular cell differentiatio n in thyroid neoplasia.